메뉴 건너뛰기




Volumn 29, Issue 1, 2019, Pages 31-40

Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis

Author keywords

Guideline; Japan College of Rheumatology; methotrexate; rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AUROTHIOMALATE; BUCILLAMINE; CYCLOSPORINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TACROLIMUS; ANTIRHEUMATIC AGENT;

EID: 85047359016     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2018.1472358     Document Type: Article
Times cited : (102)

References (111)
  • 1
    • 84930607509 scopus 로고    scopus 로고
    • Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
    • Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
    • (2016) Ann Rheum Dis , vol.75 , pp. 3-15
    • Smolen, J.S.1    Breedveld, F.C.2    Burmester, G.R.3    Bykerk, V.4    Dougados, M.5    Emery, P.6
  • 2
    • 84893772728 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
    • Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
    • (2014) Ann Rheum Dis , vol.73 , pp. 492-509
    • Smolen, J.S.1    Landewé, R.2    Breedveld, F.C.3    Buch, M.4    Burmester, G.5    Dougados, M.6
  • 3
    • 84893731584 scopus 로고    scopus 로고
    • Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
    • Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis. 2014;73:536–43.
    • (2014) Ann Rheum Dis , vol.73 , pp. 536-543
    • Takeuchi, T.1    Yamanaka, H.2    Ishiguro, N.3    Miyasaka, N.4    Mukai, M.5    Matsubara, T.6
  • 4
    • 84954360828 scopus 로고    scopus 로고
    • The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor-prognostic factors, C-OPERA, shows inhibition of radiographic progression
    • Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, et al. The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor-prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016;75:75–83.
    • (2016) Ann Rheum Dis , vol.75 , pp. 75-83
    • Atsumi, T.1    Yamamoto, K.2    Takeuchi, T.3    Yamanaka, H.4    Ishiguro, N.5    Tanaka, Y.6
  • 5
    • 45349090538 scopus 로고    scopus 로고
    • American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    • Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.
    • (2008) Arthritis Rheum , vol.59 , pp. 762-784
    • Saag, K.G.1    Teng, G.G.2    Patkar, N.M.3    Anuntiyo, J.4    Finney, C.5    Curtis, J.R.6
  • 7
    • 84891907570 scopus 로고    scopus 로고
    • JSH guidelines for the management of hepatitis B virus infection
    • Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44(S1):1–58.
    • (2014) Hepatol Res , vol.44 , Issue.S1 , pp. 1-58
  • 8
    • 33745819196 scopus 로고    scopus 로고
    • Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    • Pavy S, Constantin A, Pham T, Gosseec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388–95.
    • (2006) Joint Bone Spine , vol.73 , pp. 388-395
    • Pavy, S.1    Constantin, A.2    Pham, T.3    Gosseec, L.4    Maillefert, J.F.5    Cantagrel, A.6
  • 9
    • 67549096874 scopus 로고    scopus 로고
    • Multinational evidence-based recommendations for the arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
    • Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086–93.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1086-1093
    • Visser, K.1    Katchamart, W.2    Loza, E.3    Martinez-Lopez, J.A.4    Salliot, C.5    Trudeau, J.6
  • 10
    • 14544292345 scopus 로고    scopus 로고
    • Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis
    • Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis. Jpn J Inflammat. 1996;16:437–58.
    • (1996) Jpn J Inflammat , vol.16 , pp. 437-458
    • Kashiwazaki, S.1    Ichikawa, Y.2    Sugawara, S.3    Nagaya, I.4    Kawai, S.5    Hakota, M.6
  • 11
    • 67549101312 scopus 로고    scopus 로고
    • Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
    • Visser K, van der Heijde D., Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68:1094–9.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1094-1099
    • Visser, K.1    van der Heijde, D.2
  • 13
    • 0021709870 scopus 로고
    • A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
    • Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS., A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol. 1984;11:760–3.
    • (1984) J Rheumatol , vol.11 , pp. 760-763
    • Thompson, R.N.1    Watts, C.2    Edelman, J.3    Esdaile, J.4    Russell, A.S.5
  • 14
    • 84860736264 scopus 로고    scopus 로고
    • A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis
    • Hobl EL, Mader RM, Jilma B, Duhm B, Mustak M, Bröll H, et al. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis. Clin Ther. 2012;34:1195–203.
    • (2012) Clin Ther , vol.34 , pp. 1195-1203
    • Hobl, E.L.1    Mader, R.M.2    Jilma, B.3    Duhm, B.4    Mustak, M.5    Bröll, H.6
  • 15
    • 84918571233 scopus 로고    scopus 로고
    • Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomized, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
    • Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomized, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26.
    • (2015) Ann Rheum Dis , vol.74 , pp. 19-26
    • Emery, P.1    Burmester, G.R.2    Bykerk, V.P.3    Combe, B.G.4    Furst, D.E.5    Barré, E.6
  • 17
    • 0033596065 scopus 로고    scopus 로고
    • Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group
    • Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542–50.
    • (1999) Arch Intern Med , vol.159 , pp. 2542-2550
    • Strand, V.1    Cohen, S.2    Schiff, M.3    Weaver, A.4    Fleischmann, R.5    Cannon, G.6
  • 18
    • 3242677099 scopus 로고    scopus 로고
    • Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
    • Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9.
    • (2004) Lancet , vol.364 , pp. 263-269
    • Grigor, C.1    Capell, H.2    Stirling, A.3    McMahon, A.D.4    Lock, P.5    Vallance, R.6
  • 19
    • 35648991026 scopus 로고    scopus 로고
    • Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
    • Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443–9.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1443-1449
    • Verstappen, S.M.1    Jacobs, J.W.2    van der Veen, M.J.3    Heurkens, A.H.4    Schenk, Y.5    ter Borg, E.J.6
  • 20
    • 0027305420 scopus 로고
    • Methotrexate-the relationship between dose and clinical effect
    • Seideman P. Methotrexate-the relationship between dose and clinical effect. Br J Rheumatol. 1993;32:751–3.
    • (1993) Br J Rheumatol , vol.32 , pp. 751-753
    • Seideman, P.1
  • 21
    • 4644275370 scopus 로고    scopus 로고
    • Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis
    • Wegrzyn J, Adeleine P, Miossec P., Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232–4.
    • (2004) Ann Rheum Dis , vol.63 , pp. 1232-1234
    • Wegrzyn, J.1    Adeleine, P.2    Miossec, P.3
  • 23
    • 1842425908 scopus 로고    scopus 로고
    • Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis
    • Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M., Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31:645–8.
    • (2004) J Rheumatol , vol.31 , pp. 645-648
    • Hoekstra, M.1    Haagsma, C.2    Neef, C.3    Proost, J.4    Knuif, A.5    van de Laar, M.6
  • 24
    • 1842574679 scopus 로고
    • Bioavailability and pharmacokinetics of methotrexate (MTX) and its metabolite 7-hydroxy MTX after low dose MTX (25 mg) in patients with chronic rheumatic diseases
    • Korber H, Iven H, Gross WL., Bioavailability and pharmacokinetics of methotrexate (MTX) and its metabolite 7-hydroxy MTX after low dose MTX (25 mg) in patients with chronic rheumatic diseases. Arthritis Rheum. 1992;35(l):S142.
    • (1992) Arthritis Rheum , vol.35 , pp. S142
    • Korber, H.1    Iven, H.2    Gross, W.L.3
  • 25
    • 0016656293 scopus 로고
    • Comparison of serum concentrations of methotrexate after various routes of administration
    • Freeman-Narrod M, Gerstley BJ, Engstrom PF, Bomstein RS., Comparison of serum concentrations of methotrexate after various routes of administration. Cancer. 1975;36:1619–24.
    • (1975) Cancer , vol.36 , pp. 1619-1624
    • Freeman-Narrod, M.1    Gerstley, B.J.2    Engstrom, P.F.3    Bomstein, R.S.4
  • 26
    • 0023195465 scopus 로고
    • Methotrexate bioavailability after oral and intramuscular administration in children
    • Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE., Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr. 1987;110:788–92.
    • (1987) J Pediatr , vol.110 , pp. 788-792
    • Teresi, M.E.1    Crom, W.R.2    Choi, K.E.3    Mirro, J.4    Evans, W.E.5
  • 27
    • 38149057526 scopus 로고    scopus 로고
    • Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial
    • Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81.
    • (2008) Arthritis Rheum , vol.58 , pp. 73-81
    • Braun, J.1    Kästner, P.2    Flaxenberg, P.3    Währisch, J.4    Hanke, P.5    Demary, W.6
  • 28
    • 84903893560 scopus 로고    scopus 로고
    • Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration
    • Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549–51.
    • (2014) Ann Rheum Dis , vol.73 , pp. 1549-1551
    • Schiff, M.H.1    Jaffe, J.S.2    Freundlich, B.3
  • 29
    • 33644681620 scopus 로고    scopus 로고
    • Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis
    • Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M., Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:481–5.
    • (2006) J Rheumatol , vol.33 , pp. 481-485
    • Hoekstra, M.1    Haagsma, C.2    Neef, C.3    Proost, J.4    Knuif, A.5    van de Laar, M.6
  • 30
    • 84957582274 scopus 로고    scopus 로고
    • Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration
    • Bianchi G, Caporali R, Todoerti M, Mattana P., Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33:369–78.
    • (2016) Adv Ther , vol.33 , pp. 369-378
    • Bianchi, G.1    Caporali, R.2    Todoerti, M.3    Mattana, P.4
  • 32
    • 78650569574 scopus 로고    scopus 로고
    • Drug combinations with methotrexate to treat rheumatoid arthritis
    • Rath T, Rubbert A., Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(61):S52–S7.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.61 , pp. S52-S7
    • Rath, T.1    Rubbert, A.2
  • 33
    • 34547589468 scopus 로고    scopus 로고
    • Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs
    • Dale J, Alcorn N, Capell H, Madhok R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol. 2007;3:450–8.
    • (2007) Nat Clin Pract Rheumatol , vol.3 , pp. 450-458
    • Dale, J.1    Alcorn, N.2    Capell, H.3    Madhok, R.4
  • 34
    • 0029022389 scopus 로고
    • Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group
    • Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333:137–41.
    • (1995) N Engl J Med , vol.333 , pp. 137-141
    • Tugwell, P.1    Pincus, T.2    Yocum, D.3    Stein, M.4    Gluck, O.5    Kraag, G.6
  • 35
    • 0344237251 scopus 로고    scopus 로고
    • Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone
    • Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S., Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford). 2003;42:1545–9.
    • (2003) Rheumatology (Oxford) , vol.42 , pp. 1545-1549
    • Marchesoni, A.1    Battafarano, N.2    Arreghini, M.3    Panni, B.4    Gallazzi, M.5    Tosi, S.6
  • 36
    • 33846864259 scopus 로고    scopus 로고
    • Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study
    • Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis. 2007;66:235–41.
    • (2007) Ann Rheum Dis , vol.66 , pp. 235-241
    • Capell, H.A.1    Madhok, R.2    Porter, D.R.3    Munro, R.A.4    McInnes, I.B.5    Hunter, J.A.6
  • 37
    • 0032957015 scopus 로고    scopus 로고
    • Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
    • Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220–5.
    • (1999) Ann Rheum Dis , vol.58 , pp. 220-225
    • Dougados, M.1    Combe, B.2    Cantagrel, A.3    Goupille, P.4    Olive, P.5    Schattenkirchner, M.6
  • 38
    • 0028572390 scopus 로고
    • Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy
    • Haagsma CJ, van Riel PL, de Rooij DJ, Vree TB, Russel FJ, van’t Hof MA, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol.1994;33:1049–55.
    • (1994) Br J Rheumatol , vol.33 , pp. 1049-1055
    • Haagsma, C.J.1    van Riel, P.L.2    de Rooij, D.J.3    Vree, T.B.4    Russel, F.J.5    van’t Hof, M.A.6
  • 39
    • 0030696346 scopus 로고    scopus 로고
    • Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial
    • Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997;36:1082–8.
    • (1997) Br J Rheumatol , vol.36 , pp. 1082-1088
    • Haagsma, C.J.1    van Riel, P.L.2    de Jong, A.J.3    van de Putte, L.B.4
  • 40
    • 0037027427 scopus 로고    scopus 로고
    • Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
    • Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:726–33.
    • (2002) Ann Intern Med , vol.137 , pp. 726-733
    • Kremer, J.M.1    Genovese, M.C.2    Cannon, G.W.3    Caldwell, J.R.4    Cush, J.J.5    Furst, D.E.6
  • 41
    • 18644373869 scopus 로고    scopus 로고
    • A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study
    • Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 2005;52:1360–70.
    • (2005) Arthritis Rheum , vol.52 , pp. 1360-1370
    • Lehman, A.J.1    Esdaile, J.M.2    Klinkhoff, A.V.3    Grant, E.4    Fitzgerald, A.5    Canvin, J.6
  • 42
    • 0142135694 scopus 로고    scopus 로고
    • Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study
    • Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. 2003;48:2763–8.
    • (2003) Arthritis Rheum , vol.48 , pp. 2763-2768
    • Kremer, J.M.1    Habros, J.S.2    Kolba, K.S.3    Kaine, J.L.4    Borton, M.A.5    Mengle-Gaw, L.J.6
  • 43
    • 84880816170 scopus 로고    scopus 로고
    • Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate
    • Kitahama M, Nakajima A, Inoue E, Taniguchi A, Momohara S, Yamanaka H, et al. Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate. Mod Rheumatol. 2013;23:788–93.
    • (2013) Mod Rheumatol , vol.23 , pp. 788-793
    • Kitahama, M.1    Nakajima, A.2    Inoue, E.3    Taniguchi, A.4    Momohara, S.5    Yamanaka, H.6
  • 44
    • 84877732792 scopus 로고    scopus 로고
    • Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial
    • Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013;23:430–9.
    • (2013) Mod Rheumatol , vol.23 , pp. 430-439
    • Ishiguro, N.1    Yamamoto, K.2    Katayama, K.3    Kondo, M.4    Sumida, T.5    Mimori, T.6
  • 45
    • 84900384454 scopus 로고    scopus 로고
    • Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial
    • Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014;24:410–18.
    • (2014) Mod Rheumatol , vol.24 , pp. 410-418
    • Hara, M.1    Ishiguro, N.2    Katayama, K.3    Kondo, M.4    Sumida, T.5    Mimori, T.6
  • 46
    • 70349785354 scopus 로고    scopus 로고
    • Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis
    • Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1069–72.
    • (2009) Rheumatology (Oxford) , vol.48 , pp. 1069-1072
    • Sawada, T.1    Inokuma, S.2    Sato, T.3    Otsuka, T.4    Saeki, Y.5    Takeuchi, T.6
  • 47
    • 27744516900 scopus 로고    scopus 로고
    • Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study
    • Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323–8.
    • (2005) Mod Rheumatol , vol.15 , pp. 323-328
    • Ichikawa, Y.1    Saito, T.2    Yamanaka, H.3    Akizuki, M.4    Kondo, H.5    Kobayashi, S.6
  • 48
    • 84893721202 scopus 로고    scopus 로고
    • Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
    • Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–28.
    • (2014) Ann Rheum Dis , vol.73 , pp. 516-528
    • Nam, J.L.1    Ramiro, S.2    Gaujoux-Viala, C.3    Takase, K.4    Leon-Garcia, M.5    Emery, P.6
  • 49
    • 10744223002 scopus 로고    scopus 로고
    • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
    • Klareskog L, vander Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–81.
    • (2004) Lancet , vol.363 , pp. 675-681
    • Klareskog, L.1    vander Heijde, D.2    de Jager, J.P.3    Gough, A.4    Kalden, J.5    Malaise, M.6
  • 50
    • 79961102216 scopus 로고    scopus 로고
    • Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study
    • Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011;38:1585–92.
    • (2011) J Rheumatol , vol.38 , pp. 1585-1592
    • Kameda, H.1    Kanbe, K.2    Sato, E.3    Ueki, Y.4    Saito, K.5    Nagaoka, S.6
  • 51
    • 31044442965 scopus 로고    scopus 로고
    • The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    • Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
    • (2006) Arthritis Rheum , vol.54 , pp. 26-37
    • Breedveld, F.C.1    Weisman, M.H.2    Kavanaugh, A.F.3    Cohen, S.B.4    Pavelka, K.5    van Vollenhoven, R.6
  • 52
    • 68049099274 scopus 로고    scopus 로고
    • Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
    • Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–83.
    • (2009) Arthritis Rheum , vol.60 , pp. 2272-2283
    • Emery, P.1    Fleischmann, R.M.2    Moreland, L.W.3    Hsia, E.C.4    Strusberg, I.5    Durez, P.6
  • 53
    • 67449133560 scopus 로고    scopus 로고
    • Golimumab, a human antibody to tumour necrosisfactor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study
    • Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosisfactor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009;68:789–96.
    • (2009) Ann Rheum Dis , vol.68 , pp. 789-796
    • Keystone, E.C.1    Genovese, M.C.2    Klareskog, L.3    Hsia, E.C.4    Hall, S.T.5    Miranda, P.C.6
  • 54
    • 84922564119 scopus 로고    scopus 로고
    • Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs—a systematic review and network meta-analysis
    • Jansen JP, Buckley F, Dejonckheere F, Ogale S., Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs—a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102.
    • (2014) Health Qual Life Outcomes , vol.12 , pp. 102
    • Jansen, J.P.1    Buckley, F.2    Dejonckheere, F.3    Ogale, S.4
  • 55
    • 84930323836 scopus 로고    scopus 로고
    • Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis
    • Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP., Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm. 2015;21:409–23.
    • (2015) J Manag Care Spec Pharm , vol.21 , pp. 409-423
    • Buckley, F.1    Finckh, A.2    Huizinga, T.W.3    Dejonckheere, F.4    Jansen, J.P.5
  • 56
    • 33749363027 scopus 로고    scopus 로고
    • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    • Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.
    • (2006) Arthritis Rheum , vol.54 , pp. 2817-2829
    • Maini, R.N.1    Taylor, P.C.2    Szechinski, J.3    Pavelka, K.4    Bröll, J.5    Balint, G.6
  • 57
    • 84897971056 scopus 로고    scopus 로고
    • Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
    • Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73:803–9.
    • (2014) Ann Rheum Dis , vol.73 , pp. 803-809
    • Dougados, M.1    Kissel, K.2    Conaghan, P.G.3    Mola, E.M.4    Schett, G.5    Gerli, R.6
  • 58
    • 84956630876 scopus 로고    scopus 로고
    • Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
    • Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75:1917–23.
    • (2016) Ann Rheum Dis , vol.75 , pp. 1917-1923
    • Kaneko, Y.1    Atsumi, T.2    Tanaka, Y.3    Inoo, M.4    Kobayashi-Haraoka, H.5    Amano, K.6
  • 60
    • 84874402383 scopus 로고    scopus 로고
    • Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
    • van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–70.
    • (2013) Arthritis Rheum , vol.65 , pp. 559-570
    • van der Heijde, D.1    Tanaka, Y.2    Fleischmann, R.3    Keystone, E.4    Kremer, J.5    Zerbini, C.6
  • 61
    • 0031985832 scopus 로고    scopus 로고
    • The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials
    • Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P., The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol. 1998;25:36–43.
    • (1998) J Rheumatol , vol.25 , pp. 36-43
    • Ortiz, Z.1    Shea, B.2    Suarez-Almazor, M.E.3    Moher, D.4    Wells, G.A.5    Tugwell, P.6
  • 62
    • 0032200782 scopus 로고    scopus 로고
    • Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis
    • Pincus T., Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis. Clin Exp Rheumatol. 1998;16:667–8.
    • (1998) Clin Exp Rheumatol , vol.16 , pp. 667-668
    • Pincus, T.1
  • 63
    • 1542359519 scopus 로고    scopus 로고
    • Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review
    • Whittle SL, Hughes RA., Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43:267–71.
    • (2004) Rheumatology (Oxford) , vol.43 , pp. 267-271
    • Whittle, S.L.1    Hughes, R.A.2
  • 64
    • 78650567202 scopus 로고    scopus 로고
    • Folate supplementation during methotrexate therapy for rheumatoid arthritis
    • Morgan SL, Baggott JE., Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(61):S102–S9.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.61 , pp. S102-S9
    • Morgan, S.L.1    Baggott, J.E.2
  • 65
    • 25844483861 scopus 로고    scopus 로고
    • Folate supplementation during methotrexate therapy for patients with psoriasis
    • Strober BE, Menon K., Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53:652–9.
    • (2005) J Am Acad Dermatol , vol.53 , pp. 652-659
    • Strober, B.E.1    Menon, K.2
  • 66
    • 84901712332 scopus 로고    scopus 로고
    • Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
    • Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41:1049–60.
    • (2014) J Rheumatol , vol.41 , pp. 1049-1060
    • Shea, B.1    Swinden, M.V.2    Ghogomu, E.T.3    Ortiz, Z.4    Katchamart, W.5    Rader, T.6
  • 67
    • 0032835606 scopus 로고    scopus 로고
    • Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid
    • Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol. 1999;28:273–81.
    • (1999) Scand J Rheumatol , vol.28 , pp. 273-281
    • Suzuki, Y.1    Uehara, R.2    Tajima, C.3    Noguchi, A.4    Ide, M.5    Ichikawa, Y.6
  • 68
    • 0023785897 scopus 로고
    • The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients
    • Tishler M, Caspi D, Fishel B, Yaron M., The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988;31:906–9.
    • (1988) Arthritis Rheum , vol.31 , pp. 906-909
    • Tishler, M.1    Caspi, D.2    Fishel, B.3    Yaron, M.4
  • 69
    • 0025887372 scopus 로고
    • Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid
    • Joyce DA, Will RK, Hoffman DM, Laing B, Blackboum SJ., Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis. 1991;50:913–14.
    • (1991) Ann Rheum Dis , vol.50 , pp. 913-914
    • Joyce, D.A.1    Will, R.K.2    Hoffman, D.M.3    Laing, B.4    Blackboum, S.J.5
  • 71
    • 0035089876 scopus 로고    scopus 로고
    • Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient
    • Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44:339–42.
    • (2001) Arthritis Rheum , vol.44 , pp. 339-342
    • Ito, S.1    Nakazono, K.2    Murasawa, A.3    Mita, Y.4    Hata, K.5    Saito, N.6
  • 72
    • 2342518217 scopus 로고    scopus 로고
    • Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis
    • Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N., Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:375–6.
    • (2004) Clin Exp Rheumatol , vol.22 , pp. 375-376
    • Hagiyama, H.1    Kubota, T.2    Komano, Y.3    Kurosaki, M.4    Watanabe, M.5    Miyasaka, N.6
  • 73
    • 84862269632 scopus 로고    scopus 로고
    • Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
    • Oketani M, Ido A, Uto H, Tsubouchi H., Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627–36.
    • (2012) Hepatol Res , vol.42 , pp. 627-636
    • Oketani, M.1    Ido, A.2    Uto, H.3    Tsubouchi, H.4
  • 74
    • 79960122345 scopus 로고    scopus 로고
    • Serodiagnosis of Mycobacterium avium-complex pulmonary disease with an enzyme immunoassay kit that detects anti-glycopeptidolipid core antigen IgA antibodies in patients with rheumatoid arthritis
    • Watanabe M, Banno S, Sasaki K, Naniwa T, Hayami Y, Ueda R., Serodiagnosis of Mycobacterium avium-complex pulmonary disease with an enzyme immunoassay kit that detects anti-glycopeptidolipid core antigen IgA antibodies in patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:144–9.
    • (2011) Mod Rheumatol , vol.21 , pp. 144-149
    • Watanabe, M.1    Banno, S.2    Sasaki, K.3    Naniwa, T.4    Hayami, Y.5    Ueda, R.6
  • 75
    • 0028939349 scopus 로고
    • The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group
    • The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol. 1995;22:218–23.
    • (1995) J Rheumatol , vol.22 , pp. 218-223
  • 76
    • 0030000725 scopus 로고    scopus 로고
    • Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines
    • Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 1996;39:723–31.
    • (1996) Arthritis Rheum , vol.39 , pp. 723-731
  • 77
    • 4444369382 scopus 로고    scopus 로고
    • Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis
    • Kent PD, Luthra HS, Michet C, Jr. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol. 2004;31:1727–31.
    • (2004) J Rheumatol , vol.31 , pp. 1727-1731
    • Kent, P.D.1    Luthra, H.S.2    Michet, C.3
  • 78
    • 77649199610 scopus 로고    scopus 로고
    • Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1,415 patients)
    • Cheung PP, Dougados M, Gossec L., Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1,415 patients). Arthritis Care Res. 2010;62:323–34.
    • (2010) Arthritis Care Res , vol.62 , pp. 323-334
    • Cheung, P.P.1    Dougados, M.2    Gossec, L.3
  • 80
    • 72949115688 scopus 로고    scopus 로고
    • A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control
    • Loza E, Martinez-Lopez JA, Carmona L., A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol. 2009;27:856–62.
    • (2009) Clin Exp Rheumatol , vol.27 , pp. 856-862
    • Loza, E.1    Martinez-Lopez, J.A.2    Carmona, L.3
  • 81
    • 51549091222 scopus 로고    scopus 로고
    • The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis
    • Pieringer H, Stuby U, Biesenbach G., The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol. 2008;27:1217–20.
    • (2008) Clin Rheumatol , vol.27 , pp. 1217-1220
    • Pieringer, H.1    Stuby, U.2    Biesenbach, G.3
  • 82
    • 34047163955 scopus 로고    scopus 로고
    • Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment?
    • Pieringer H, Stuby U, Biesenbach G., Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin Arthritis Rheum. 2007;36:278–86.
    • (2007) Semin Arthritis Rheum , vol.36 , pp. 278-286
    • Pieringer, H.1    Stuby, U.2    Biesenbach, G.3
  • 83
    • 0026026468 scopus 로고
    • Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate
    • Perhala RS, Wilke WS, Clough JD, Segal AM., Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum. 1991;34:146–52.
    • (1991) Arthritis Rheum , vol.34 , pp. 146-152
    • Perhala, R.S.1    Wilke, W.S.2    Clough, J.D.3    Segal, A.M.4
  • 84
    • 33644507068 scopus 로고    scopus 로고
    • Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery
    • Murata K, Yasuda T, Ito H, Yoshida M, Shimizu M, Nakajima T., Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol. 2006;16:14–19.
    • (2006) Mod Rheumatol , vol.16 , pp. 14-19
    • Murata, K.1    Yasuda, T.2    Ito, H.3    Yoshida, M.4    Shimizu, M.5    Nakajima, T.6
  • 85
    • 0027303840 scopus 로고
    • Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis
    • Sany J, Anaya JM, Canovas F, Combe B, Jorgensen C, Saker S, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol. 1993;20:1129–32.
    • (1993) J Rheumatol , vol.20 , pp. 1129-1132
    • Sany, J.1    Anaya, J.M.2    Canovas, F.3    Combe, B.4    Jorgensen, C.5    Saker, S.6
  • 86
    • 0035089096 scopus 로고    scopus 로고
    • Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery
    • Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60:214–17.
    • (2001) Ann Rheum Dis , vol.60 , pp. 214-217
    • Grennan, D.M.1    Gray, J.2    Loudon, J.3    Fear, S.4
  • 87
    • 0025767122 scopus 로고
    • Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?
    • Bridges SL, Jr, López-Méndez A, Han KH, Tracy IC, Alarcón GS., Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol. 1991;18:984–8.
    • (1991) J Rheumatol , vol.18 , pp. 984-988
    • Bridges, S.L.1    López-Méndez, A.2    Han, K.H.3    Tracy, I.C.4    Alarcón, G.S.5
  • 88
    • 0029981838 scopus 로고    scopus 로고
    • Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy
    • Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE., Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics. 1996;19:207–10.
    • (1996) Orthopedics , vol.19 , pp. 207-210
    • Carpenter, M.T.1    West, S.G.2    Vogelgesang, S.A.3    Casey Jones, D.E.4
  • 90
    • 84959378744 scopus 로고    scopus 로고
    • The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
    • Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
    • (2016) Ann Rheum Dis , vol.75 , pp. 795-810
    • Götestam Skorpen, C.1    Hoeltzenbein, M.2    Tincani, A.3    Fischer-Betz, R.4    Elefant, E.5    Chambers, C.6
  • 92
    • 84923227527 scopus 로고    scopus 로고
    • Methotrexate use in a breastfeeding patient with rheumatoid arthritis
    • Thorne JC, Nadarajah T, Moretti M, Ito S., Methotrexate use in a breastfeeding patient with rheumatoid arthritis. J Rheumatol. 2014;41:2332.
    • (2014) J Rheumatol , vol.41 , pp. 2332
    • Thorne, J.C.1    Nadarajah, T.2    Moretti, M.3    Ito, S.4
  • 93
    • 84897532072 scopus 로고    scopus 로고
    • Rheumatoid arthritis medications and lactation
    • Sammaritano LR, Bermas BL., Rheumatoid arthritis medications and lactation. Curr Opin Rheumatol. 2014;26:354–60.
    • (2014) Curr Opin Rheumatol , vol.26 , pp. 354-360
    • Sammaritano, L.R.1    Bermas, B.L.2
  • 94
    • 0027174534 scopus 로고
    • Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice
    • Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993;20:639–44.
    • (1993) J Rheumatol , vol.20 , pp. 639-644
    • Buchbinder, R.1    Hall, S.2    Sambrook, P.N.3    Champion, G.D.4    Harkness, A.5    Lewis, D.6
  • 96
    • 22144458739 scopus 로고    scopus 로고
    • Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999
    • Kuitunen T, Maimström J, Palva E, Pettersson T., Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999. Scand J Rheumatol. 2005;34:238–41.
    • (2005) Scand J Rheumatol , vol.34 , pp. 238-241
    • Kuitunen, T.1    Maimström, J.2    Palva, E.3    Pettersson, T.4
  • 97
    • 24944511275 scopus 로고    scopus 로고
    • Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years
    • Lim AY, Gaffney K, Scott DG., Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005;44:1051–5.
    • (2005) Rheumatology (Oxford) , vol.44 , pp. 1051-1055
    • Lim, A.Y.1    Gaffney, K.2    Scott, D.G.3
  • 98
    • 12344297751 scopus 로고    scopus 로고
    • The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions
    • Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF., The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005;44:61–6.
    • (2005) Rheumatology (Oxford) , vol.44 , pp. 61-66
    • Kinder, A.J.1    Hassell, A.B.2    Brand, J.3    Brownfield, A.4    Grove, M.5    Shadforth, M.F.6
  • 99
    • 1242342218 scopus 로고    scopus 로고
    • Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis
    • Saravanan V, Kelly CA., Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:143–7.
    • (2004) Rheumatology (Oxford) , vol.43 , pp. 143-147
    • Saravanan, V.1    Kelly, C.A.2
  • 100
    • 0033964302 scopus 로고    scopus 로고
    • Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients
    • Imokawa S, Colby TV, Leslie KO, Helmers RA., Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15:373–81.
    • (2000) Eur Respir J , vol.15 , pp. 373-381
    • Imokawa, S.1    Colby, T.V.2    Leslie, K.O.3    Helmers, R.A.4
  • 101
    • 17044442903 scopus 로고    scopus 로고
    • Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group
    • Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356–64.
    • (1997) Ann Intern Med , vol.127 , pp. 356-364
    • Alarcón, G.S.1    Kremer, J.M.2    Macaluso, M.3    Weinblatt, M.E.4    Cannon, G.W.5    Palmer, W.R.6
  • 102
    • 0031440296 scopus 로고    scopus 로고
    • Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis
    • Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24:2299–303.
    • (1997) J Rheumatol , vol.24 , pp. 2299-2303
    • Ohosone, Y.1    Okano, Y.2    Kameda, H.3    Fujii, T.4    Hama, N.5    Hirakata, M.6
  • 103
    • 84887621217 scopus 로고    scopus 로고
    • Consensus statement for the diagnosis and treatment of drug-induced lung injuries
    • Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51:260–77.
    • (2013) Respir Investig , vol.51 , pp. 260-277
    • Kubo, K.1    Azuma, A.2    Kanazawa, M.3    Kameda, H.4    Kusumoto, M.5    Genma, A.6
  • 105
    • 84865624563 scopus 로고    scopus 로고
    • Development and validation of a risk score for serious infection in patients with rheumatoid arthritis
    • Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL., Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:2847–55.
    • (2012) Arthritis Rheum , vol.64 , pp. 2847-2855
    • Crowson, C.S.1    Hoganson, D.D.2    Fitz-Gibbon, P.D.3    Matteson, E.L.4
  • 106
    • 44649131357 scopus 로고    scopus 로고
    • Incidence of lymphoma in patients with rheumatoid arthritis: systematic review of the literature
    • Kaiser R., Incidence of lymphoma in patients with rheumatoid arthritis: systematic review of the literature. Clin Lymphoma Myeloma. 2008;8:87–93.
    • (2008) Clin Lymphoma Myeloma , vol.8 , pp. 87-93
    • Kaiser, R.1
  • 107
    • 84940487042 scopus 로고    scopus 로고
    • Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population
    • Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42:564–71.
    • (2015) J Rheumatol , vol.42 , pp. 564-571
    • Hashimoto, A.1    Chiba, N.2    Tsuno, H.3    Komiya, A.4    Furukawa, H.5    Matsui, T.6
  • 109
    • 84939167646 scopus 로고    scopus 로고
    • Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
    • Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S., Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212–21.
    • (2015) Arthritis Res Ther , vol.17 , pp. 212-221
    • Simon, T.A.1    Thompson, A.2    Gandhi, K.K.3    Hochberg, M.C.4    Suissa, S.5
  • 110
    • 33644892763 scopus 로고    scopus 로고
    • Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
    • Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.
    • (2006) Arthritis Rheum , vol.54 , pp. 692-701
    • Baecklund, E.1    Iliadou, A.2    Askling, J.3    Ekbom, A.4    Backlin, C.5    Granath, F.6
  • 111
    • 84906685237 scopus 로고    scopus 로고
    • Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients
    • Kameda T, Dobashi H, Miyatake N, Inoo M, Onishi I, Kurata N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2014;66:1302–9.
    • (2014) Arthritis Care Res (Hoboken) , vol.66 , pp. 1302-1309
    • Kameda, T.1    Dobashi, H.2    Miyatake, N.3    Inoo, M.4    Onishi, I.5    Kurata, N.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.